LABBÉ, Catherine, Kotaro OGAKI, Oswaldo LORENZO-BETANCOR, Alexandra I. SOTO-ORTOLAZA, Ronald L. WALTON, Sruti RAYAPROLU, Shinsuke FUJIOKA, Melissa E. MURRAY, Michael G. HECKMAN, Andreas PUSCHMANN, Allan MCCARTHY, Timothy LYNCH, Joanna SIUDA, Grzegorz OPALA, Monika RUDZINSKA, Anna KRYGOWSKA-WAJS, Maria BARCIKOWSKA, Krzysztof CZYZEWSKI, Yanosh SANOTSKY, Irena REKTOROVÁ, Pamela J. MCLEAN, Rosa RADEMAKERS, Niluefer ERTEKIN-TANER, Anhar HASSAN, J. Eric AHLSKOG, Bradley F. BOEVE, Ronald C. PETERSEN, Demetrius M. MARAGANORE, Charles H. ADLER, Tanis J. FERMAN, Joseph E. PARISI, Neill R. GRAFF-RADFORD, Ryan J. UITTI, Zbigniew K. WSZOLEK, Dennis W. DICKSON and Owen A. ROSS. Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies. Neurology. Philadelphia: LIPPINCOTT WILLIAMS & WILKINS, 2015, vol. 85, No 19, p. 1680-1686. ISSN 0028-3878. Available from: https://dx.doi.org/10.1212/WNL.0000000000001946.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies
Authors LABBÉ, Catherine (840 United States of America), Kotaro OGAKI (840 United States of America), Oswaldo LORENZO-BETANCOR (840 United States of America), Alexandra I. SOTO-ORTOLAZA (840 United States of America), Ronald L. WALTON (840 United States of America), Sruti RAYAPROLU (840 United States of America), Shinsuke FUJIOKA (840 United States of America), Melissa E. MURRAY (840 United States of America), Michael G. HECKMAN (840 United States of America), Andreas PUSCHMANN (752 Sweden), Allan MCCARTHY (372 Ireland), Timothy LYNCH (372 Ireland), Joanna SIUDA (616 Poland), Grzegorz OPALA (616 Poland), Monika RUDZINSKA (616 Poland), Anna KRYGOWSKA-WAJS (616 Poland), Maria BARCIKOWSKA (616 Poland), Krzysztof CZYZEWSKI (616 Poland), Yanosh SANOTSKY (804 Ukraine), Irena REKTOROVÁ (203 Czech Republic, guarantor, belonging to the institution), Pamela J. MCLEAN (840 United States of America), Rosa RADEMAKERS (840 United States of America), Niluefer ERTEKIN-TANER (840 United States of America), Anhar HASSAN (840 United States of America), J. Eric AHLSKOG (840 United States of America), Bradley F. BOEVE (840 United States of America), Ronald C. PETERSEN (840 United States of America), Demetrius M. MARAGANORE (840 United States of America), Charles H. ADLER (840 United States of America), Tanis J. FERMAN (840 United States of America), Joseph E. PARISI (840 United States of America), Neill R. GRAFF-RADFORD (840 United States of America), Ryan J. UITTI (840 United States of America), Zbigniew K. WSZOLEK (840 United States of America), Dennis W. DICKSON (840 United States of America) and Owen A. ROSS (840 United States of America).
Edition Neurology, Philadelphia, LIPPINCOTT WILLIAMS & WILKINS, 2015, 0028-3878.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.166
RIV identification code RIV/00216224:14740/15:00085057
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1212/WNL.0000000000001946
UT WoS 000364338500009
Keywords in English adult; aged; alpha synucleinopathies; Article; case control study; controlled study; degenerative disease; diffuse Lewy body disease; disease predisposition
Tags podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Eva Špillingová, učo 110713. Changed: 4/4/2016 15:00.
Abstract
Objective: To assess the importance of MAPT variant p.A152T in the risk of synucleinopathies. Methods: In this case-control study, we screened a large global series of patients and controls, and assessed associations between p.A152T and disease risk. We included 3,229 patients with clinical Parkinson disease (PD), 442 with clinical dementia with Lewy bodies (DLB), 181 with multiple system atrophy (MSA), 832 with pathologically confirmed Lewy body disease (LBD), and 2,456 healthy controls. Results: The minor allele frequencies (MAF) in clinical PD cases (0.28%) and in controls (0.2%) were not found to be significantly different (odds ratio [OR] 1.37, 95% confidence interval [CI] 0.63-2.98, p 0.42). However, a significant association was observed with clinical DLB (MAF 0.68%, OR 5.76, 95% CI 1.62-20.51, p 0.007) and LBD (MAF 0.42%, OR 3.55, 95% CI 1.04-12.17, p 0.04). Additionally, p.A152T was more common in patients with MSA compared to controls (MAF 0.55%, OR 4.68, 95% CI 0.85-25.72, p 0.08) but this was not statistically significant and therefore should be interpreted with caution. Conclusions: Overall, our findings suggest that MAPT p.A152T is a rare low penetrance variant likely associated with DLB that may be influenced by coexisting LBD and AD pathology. Given the rare nature of the variant, further studies with greater sample size are warranted and will help to fully explain the role of p.A152T in the pathogenesis of the synucleinopathies. © 2015 American Academy of Neurology.
PrintDisplayed: 27/9/2024 00:11